Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure.
Plasma and tissue concentrations of amphotericin B were determined in a patient treated with liposomal amphotericin B during liver transplant failure. A cumulative rise in amphotericin B plasma concentrations was observed accompanied by an enhanced pulmonary deposition of the drug. Failure of the liver as a major component of the reticuloendothelial system may cause elevated plasma concentrations of liposomal amphotericin B and may consequently enhance deposition of liposomes in the lungs as a substitutive clearing organ.
Heinemann
V
V
Klinikum Grosshadern, III Medical Clinic, University of Munich, Germany.
Bosse
D
D
Jehn
U
U
Debus
A
A
Wachholz
K
K
Forst
H
H
Wilmanns
W
W
D000208:Acute Disease; D000666:Amphotericin B / Q000097:blood / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000097:blood / Q000493:pharmacokinetics*; D017809:Fatal Outcome; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008081:Liposomes / Q000378:metabolism; D017093:Liver Failure / Q000378:metabolism*; D016031:Liver Transplantation; D008168:Lung / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B